VIDEO: PCSK9 inhibitors show benefit in high-risk groups

PHILADELPHIA — In this video exclusive, Pam R. Taub, MD, FACC, cardiologist and associate professor of medicine at University of California, San Diego, highlights the benefits of PCSK9 inhibitors in high-risk patients.
Taub discusses recent data that have demonstrated benefit of PCSK9 inhibitors for reducing major adverse CV events and in subgroups of high-risk patients such as those with multivessel disease, peripheral artery disease, type 2 diabetes and elevated lipoprotein A.
Watch the video for more.

Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.